Login to Your Account



Zybrestat's Phase II Ovarian Cancer Trial Passes Review

By Catherine Shaffer
Staff Writer

Thursday, February 7, 2013
Shares of OxiGene Inc. bounced 14.8 percent Thursday on news that its Phase II study of Zybrestat and Avastin in ovarian cancer demonstrated acceptable tolerability in an interim toxicity analysis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription